Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain

Phase 1 Terminated 5 enrolled Xalud Therapeutics, Inc.

RandomizedSequentialQuadruple-blindTreatment

Summary

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain. Intrathecally administered, single injection.

Timeline

Start: 2021-04-14
Primary completion: 2022-09-27
Completion: 2022-09-27

Outcome

Outcome not reported

Stopped (Enrollment): “Failure to enroll a sufficient number of patients.”

Publications

Kanao-Kanda M, Kanda H, Liu S, Kawamata T, Candiotti KA, Hao S. Viral vector-mediated interleukin 10 for gene therapy on chronic pain. Mol Pain. 2025 Jan-Dec;21:17448069251390266. doi: 10.1177/17448069251390266. Epub 2025 Oct 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XT-150	Other / unclassified	0.015 mg	Intrathecal
Subject	XT-150	Other / unclassified	0.15 mg	Intrathecal
Subject	XT-150	Other / unclassified	0.45 mg	Intrathecal